{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"110","value":"143"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"483"}],"units":"Participants"}],"description":"Pharmacokinetics (PK): Minimum Steady State Concentration (Cmin,ss) of Abemaciclib","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received Abemaciclib orally at 150 milligrams (mg) twice daily with at least 6 hours between doses for up to 2 years or until evidence of disease recurrence or other discontinuation criteria were met, whichever occurs first. Endocrine therapy (physicians' choice) standard-of-care was administered according to package label until discontinuation criteria were met.","id":"OG000","title":"150 mg Abemaciclib + Endocrine Therapy"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All randomized participants who received at least one dose of Abemaciclib and had evaluable PK data.","reportingStatus":"POSTED","timeFrame":"Day 1 (2 hours post-dose), Days 30, 60, 90 post-dose","title":"Pharmacokinetics (PK): Minimum Steady State Concentration (Cmin,ss) of Abemaciclib","type":"SECONDARY","unitOfMeasure":"Nanograms per milliliter (ng/mL)"}